When the word ‘coronavirus’ entered the general consciousness in early 2020, little did we know the extent to which this new disease would essentially press pause on our daily lives. The true ramifications of lockdowns, social distancing, self-isolation, as well as hospital closures caused by the pandemic are as yet unknown, and will likely reverberate for a generation.
What we do know is across several weeks of firefighting to respond to the immediate situation, clinical trial sponsors have not yet got to thinking about what happens next. Clearly the current challenges are daunting. There’s a lot that needs to happen before we start thinking about patients travelling to sites again for their regular visits, but it’s worth starting to consider what happens when pharma companies do decide to press the ‘go’ button again.
|
